What is US Biologic?
US Biologic operates at the intersection of immunology and advanced delivery science, specializing in the development of oral vaccine technologies. The company's core mission is to combat the spread of infectious diseases, including tick-borne illnesses such as Lyme disease and various pandemic-level threats. By moving away from traditional injection-based methods, US Biologic provides a versatile platform that serves healthcare providers, agricultural entities, and animal health organizations. Their market position is defined by a commitment to enhancing global health security through innovative, field-deployable vaccine delivery systems that simplify immunization logistics and improve patient compliance across diverse environments.
How much funding has US Biologic raised?
US Biologic has raised a total of $1.1M across 2 funding rounds:
Debt
$1M
Debt
$106K
Debt (2017): $1M, investors not publicly disclosed
Debt (2021): $106K led by PPP
Key Investors in US Biologic
PPP
Public-Private Partnership
Undisclosed Investor
A private capital provider participating in the company's debt financing rounds to facilitate long-term research and development initiatives.
Undisclosed Investor
An undisclosed investor participating in the funding round to support the advancement of oral vaccine delivery technologies.
What's next for US Biologic?
With the infusion of this major strategic investment, US Biologic is expected to transition into a phase of rapid commercial scaling and expanded clinical validation. The company will likely prioritize the optimization of its delivery mechanisms to ensure broader efficacy across different species and disease vectors. Future growth will be driven by the integration of these technologies into existing public health frameworks, potentially establishing new standards for pandemic prevention and zoonotic disease control. As the firm continues to refine its intellectual property, stakeholders anticipate a significant increase in operational capacity and the potential for strategic partnerships with global health organizations to address emerging biological threats.
See full US Biologic company page
